The Latest in AML

Clinical trials summary: AGILE

October 11, 2017

AML

Flotetuzumab for AML passes phase 1 test

September 21, 2017

AML

AML risk is doubled in low-risk thyroid cancer patients unnecessarily given radioactive iodine therapy

September 18, 2017

AML

New AML approvals changing the treatment landscape

September 8, 2017

AML

FDA reapproves gemtuzumab ozogamicin for CD33-positive AML treatment

September 1, 2017

Enasidenib data in IDH2-mutated AML are basis for combination therapy trials

August 28, 2017

AML

Hospice care underused in older patients with de novo AML

August 14, 2017

Liposomal daunorubicin and cytarabine approved for t-AML, AML-MRC

August 3, 2017

AML

Enasidenib gets FDA approval for AML with IDH2 mutations

August 1, 2017

AML

Venetoclax-HMA combo promising for AML in patients 65+

July 14, 2017

AML

Enasidenib monotherapy responses in 37% with relapsed/refractory AML and IDH2 mutations

July 11, 2017

AML

Midostaurin improves survival in new AML

June 24, 2017

AML

Gilteritinib shows safety, efficacy in relapsed/refractory AML

June 24, 2017

AML

Antibody from AML survivor may prove therapeutic

June 23, 2017

AML

Longer course of idarubicin consolidation increases leukemia-free survival

April 30, 2017

AML